PLX רווחיות לפי רווח גולמי Protalix BioTherapeutics Inc.

Israeli developer Protalix BioTherapeutics is feeling the impact of local instability in the Middle East, although the humanitarian status of its medications supports the business. Industry risks include the vulnerability of raw material supply chains and challenges with foreign certification. The gross margin ratio clearly demonstrates pricing power, with the indicator standing at 71.20. Protalix BioTherapeutics is focusing on the commercialization of therapies for rare pathologies, utilizing its innovative ProCellEx platform to reduce protein synthesis costs.
פילוחים אנליטיים ודוחות נתונים של חברת Protalix BioTherapeutics Inc. (PLX)

Gross margin determines the share of profit after deducting direct production costs, serving as a key indicator of the issuer's operational efficiency and pricing power. By analyzing gross margin volatility, an investor assesses the ability of Protalix BioTherapeutics (PLX) to monetize its unique developments in plant-based protein expression, which confirms the high value of breakthrough enzyme therapies for treating rare genetic pathologies.